Exploring the Potential of Endophytes from Medicinal Plants As Sources of Antimycobacterial Compounds

Overview

Journal Microbiol Res

Specialties Biotechnology
Environmental Health
Microbiology

Date 2014 Mar 4

PMID 24582778

Citations 75

Authors

Alfonsus Alvin

Kristin I Miller

Brett A Neilan

Affiliations

Soon will be listed here.

Abstract

Natural product drug discovery has regained interest due to low production costs, structural diversity, and multiple uses of active compounds to treat various diseases. Attention has been directed towards medicinal plants as these plants have been traditionally used for generations to treat symptoms of numerous diseases. It is established that plants harbour microorganisms, collectively known as endophytes. Exploring the as-yet untapped natural products from the endophytes increases the chances of finding novel compounds. The concept of natural products targeting microbial pathogens has been applied to isolate novel antimycobacterial compounds, and the rapid development of drug-resistant Mycobacterium tuberculosis has significantly increased the need for new treatments against this pathogen. It remains important to continuously screen for novel compounds from natural sources, particularly from rarely encountered microorganisms, such as the endophytes. This review focuses on bioprospecting for polyketides and small peptides exhibiting antituberculosis activity, although current treatments against tuberculosis are described. It is established that natural products from these structure classes are often biosynthesised by microorganisms. Therefore it is hypothesised that some bioactive polyketides and peptides originally isolated from plants are in fact produced by their endophytes. This is of interest for further endophyte natural product investigations.

Citing Articles

Nuclear Magnetic Resonance Fingerprinting and Principal Component Analysis Strategies Lead to Anti-Tuberculosis Natural Product Discovery from Actinomycetes.

Han J, Liu X, Zhang L, Quinn R, Liu M Antibiotics (Basel). 2025; 14(1).

PMID: 39858393 PMC: 11763000. DOI: 10.3390/antibiotics14010108.

Endophytic bacteria: a sustainable strategy for enhancing medicinal plant cultivation and preserving microbial diversity.

Semenzato G, Fani R Front Microbiol. 2024; 15:1477465.

PMID: 39624715 PMC: 11609176. DOI: 10.3389/fmicb.2024.1477465.

Bioactive Compounds Produced by Endophytic Bacteria and Their Plant Hosts-An Insight into the World of Chosen Herbaceous Ruderal Plants in Central Europe.

Drozdzynski P, Rutkowska N, Rodziewicz M, Marchut-Mikolajczyk O Molecules. 2024; 29(18).

PMID: 39339451 PMC: 11433698. DOI: 10.3390/molecules29184456.

Plant growth promoting activities of endophytic bacteria from (Meliaceae) and their influence on plant growth under gnotobiotic conditions.

Ramirez C, Cardozo M, Lopez Gaston M, Galdeano E, Collavino M Heliyon. 2024; 10(15):e35814.

PMID: 39170558 PMC: 11337034. DOI: 10.1016/j.heliyon.2024.e35814.

Endophytic fungi: A future prospect for breast cancer therapeutics and drug development.

Varghese S, Jisha M, Rajeshkumar K, Gajbhiye V, Alrefaei A, Jeewon R Heliyon. 2024; 10(13):e33995.

PMID: 39091955 PMC: 11292557. DOI: 10.1016/j.heliyon.2024.e33995.

References

Manjunatha U, Boshoff H, Dowd C, Zhang L, Albert T, Norton J . Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2006; 103(2):431-6. PMC: 1326169. DOI: 10.1073/pnas.0508392103. View

Cheng Y . Deciphering the biosynthetic codes for the potent anti-SARS-CoV cyclodepsipeptide valinomycin in Streptomyces tsusimaensis ATCC 15141. Chembiochem. 2006; 7(3):471-7. PMC: 7162017. DOI: 10.1002/cbic.200500425. View

Alangaden G, Kreiswirth B, Aouad A, Khetarpal M, Igno F, Moghazeh S . Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998; 42(5):1295-7. PMC: 105813. DOI: 10.1128/AAC.42.5.1295. View

Mukai A, Fukai T, Hoshino Y, Yazawa K, Harada K, Mikami Y . Nocardithiocin, a novel thiopeptide antibiotic, produced by pathogenic Nocardia pseudobrasiliensis IFM 0757. J Antibiot (Tokyo). 2009; 62(11):613-9. DOI: 10.1038/ja.2009.90. View

Caceres N, Harris N, Wellehan J, Feng Z, Kapur V, Barletta R . Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in Mycobacterium smegmatis. J Bacteriol. 1997; 179(16):5046-55. PMC: 179361. DOI: 10.1128/jb.179.16.5046-5055.1997. View

Drlica K, Zhao X . DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997; 61(3):377-92. PMC: 232616. DOI: 10.1128/mmbr.61.3.377-392.1997. View

Farnsworth N, Akerele O, Bingel A, Soejarto D, Guo Z . Medicinal plants in therapy. Bull World Health Organ. 1985; 63(6):965-81. PMC: 2536466. View

Xu H, Jiang R, Xiao H . Clofazimine in the treatment of multidrug-resistant tuberculosis. Clin Microbiol Infect. 2011; 18(11):1104-10. DOI: 10.1111/j.1469-0691.2011.03716.x. View

Rawlings B . Type I polyketide biosynthesis in bacteria (Part A--erythromycin biosynthesis). Nat Prod Rep. 2001; 18(2):190-227. DOI: 10.1039/b009329g. View

10.

Isaka M, Palasarn S, Supothina S, Komwijit S, Luangsa-Ard J . Bioactive compounds from the scale insect pathogenic fungus Conoideocrella tenuis BCC 18627. J Nat Prod. 2011; 74(4):782-9. DOI: 10.1021/np100849x. View

11.

Gurib-Fakim A . Medicinal plants: traditions of yesterday and drugs of tomorrow. Mol Aspects Med. 2005; 27(1):1-93. DOI: 10.1016/j.mam.2005.07.008. View

12.

Strobel G, Daisy B, Castillo U, Harper J . Natural products from endophytic microorganisms. J Nat Prod. 2004; 67(2):257-68. DOI: 10.1021/np030397v. View

13.

Dancik V, Seiler K, Young D, Schreiber S, Clemons P . Distinct biological network properties between the targets of natural products and disease genes. J Am Chem Soc. 2010; 132(27):9259-61. PMC: 2898216. DOI: 10.1021/ja102798t. View

14.

Walters W, Namchuk M . Designing screens: how to make your hits a hit. Nat Rev Drug Discov. 2003; 2(4):259-66. DOI: 10.1038/nrd1063. View

15.

Hertweck C, Luzhetskyy A, Rebets Y, Bechthold A . Type II polyketide synthases: gaining a deeper insight into enzymatic teamwork. Nat Prod Rep. 2007; 24(1):162-90. DOI: 10.1039/b507395m. View

16.

Cohen J . Infectious disease. Approval of novel TB drug celebrated--with restraint. Science. 2013; 339(6116):130. DOI: 10.1126/science.339.6116.130. View

17.

Scorpio A, Heifets L, Gilman R, Siddiqi S, Cynamon M, Zhang Y . Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1997; 41(3):540-3. PMC: 163747. DOI: 10.1128/AAC.41.3.540. View

18.

Alangaden G, Manavathu E, Vakulenko S, Zvonok N, Lerner S . Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob Agents Chemother. 1995; 39(8):1700-3. PMC: 162811. DOI: 10.1128/AAC.39.8.1700. View

19.

Puri S, Verma V, Amna T, Nabi Qazi G, Spiteller M . An endophytic fungus from Nothapodytes foetida that produces camptothecin. J Nat Prod. 2005; 68(12):1717-9. DOI: 10.1021/np0502802. View

20.

Verpoorte R . Pharmacognosy in the new millennium: leadfinding and biotechnology. J Pharm Pharmacol. 2000; 52(3):253-62. DOI: 10.1211/0022357001773931. View